News
Please, enter cell line, author or any other phrase or word you would like to search for.
Interim Report 1 2021/22
The strategic shift of sales and marketing continues to prove itself. Despite being a “slow summer quarter”, sales during May – July surpassed sales during any previous quarter.
PHI Enters Regenerative Medicine Partnership
PHI and RegenMed Development Organization have entered a partnership to advance large-scale biomanufacturing of cell-based therapies.
Year-end Report 2020/21
The strategic shift to focus on digital sales & marketing has been successful, reflected in the sales increase during the latter part of the fiscal year.
Growing Number of Bio-engineering Companies Purchase HoloMonitor
The regenerative medicine company Pandorum Technology recently purchased a complete HoloMonitor system.
Sahlgrenska Acquires Second HoloMonitor System
After an initial purchase by Sahlgrenska University Hospital, Sahlgrenska Center for Cancer Research acquires a second HoloMonitor system.
BioSpherix Partnership Yields HoloMonitor Customer in Regenerative Medicine
Recently, the EU-funded Centre for Innovative Medicine in Vilnius purchased its first HoloMonitor analyzer for use in the center’s incubator system from BioSpherix.
Harvard Researchers Purchase HoloMonitor
Partners HealthCare International in Boston, Massachusetts, recently ordered its first and fully equipped HoloMonitor unit.
Interim Report 3 (2020-11-01 – 2021-01-31)
The second wave of the pandemic restricted sales during the 3rd quarter. However, the situation has improved significantly since late January.
PHI Secure Working Capital Until 2023
PHI has received a second loan commitment of 20 MSEK. In total, the company has received loan commitments of 35 MSEK that are expected to secure the company’s working capital until 2023.
Interim Report 2 (2020-08-01 – 2020-10-31)
The relaxed COVID-19 restrictions during the 2nd quarter led to a noticeable increase in sales.